Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer

A National Cancer Database analysis

Corey C. Foster, David J Sher, Chad G. Rusthoven, Vivek Verma, Michael T. Spiotto, Ralph R. Weichselbaum, Matthew Koshy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Preclinical studies suggest enhanced anti-tumor activity with combined radioimmunotherapy. We hypothesized that radiation (RT) + immunotherapy would associate with improved overall survival (OS) compared to immunotherapy or chemotherapy alone for patients with newly diagnosed metastatic non-small-cell lung cancer (NSCLC). Methods: The National Cancer Database was queried for patients with stage IV NSCLC receiving chemotherapy or immunotherapy from 2013 to 2014. RT modality was classified as stereotactic radiotherapy (SRT) to intra- and/or extracranial sites or non-SRT external beam RT (EBRT). OS was analyzed using the Kaplan-Meier method and Cox proportional hazards models. Results: In total, 44,498 patients were included (13% immunotherapy, 46.8% EBRT, and 4.7% SRT). On multivariate analysis, immunotherapy (hazard ratio [HR]:0.81, 95% confidence interval [CI]:0.78-0.83) and SRT (HR:0.78, 95%CI:0.70-0.78) independently associated with improved OS; however, the interaction term for SRT + immunotherapy was insignificant (p = 0.89). For immunotherapy patients, the median OS for no RT, EBRT, and SRT was 14.5, 10.9, and 18.2 months, respectively (p < 0.0001), and EBRT (HR:1.37, 95%CI:1.29-1.46) and SRT (HR:0.78, 95%CI:0.66-0.93) associated with OS on multivariate analysis. In the SRT subset, median OS for immunotherapy and chemotherapy was 18.2 and 14.3 months, respectively (p = 0.004), with immunotherapy (HR:0.82, 95%CI:0.69-0.98) associating with OS on multivariate analysis. Furthermore, for patients receiving SRT, biologically effective dose (BED) > 60 Gy was independently associated with improved OS (HR:0.79, 95%CI:0.70-0.90, p < 0.0001) on multivariate analysis with a significant interaction between BED and systemic treatment (p = 0.008). Conclusions: Treatment with SRT associated with improved OS for patients with metastatic NSCLC irrespective of systemic treatment. The high survival for patients receiving SRT + immunotherapy strongly argues for evaluation in randomized trials.

Original languageEnglish (US)
Article number18
JournalRadiation Oncology
Volume14
Issue number1
DOIs
StatePublished - Jan 28 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Radiotherapy
Databases
Radiation
Survival
Neoplasms
Confidence Intervals
Therapeutics
Multivariate Analysis
Radioimmunotherapy
Drug Therapy
Proportional Hazards Models

Keywords

  • Immunotherapy
  • National Cancer Database
  • Non-small-cell lung cancer
  • Radioimmunotherapy
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer : A National Cancer Database analysis. / Foster, Corey C.; Sher, David J; Rusthoven, Chad G.; Verma, Vivek; Spiotto, Michael T.; Weichselbaum, Ralph R.; Koshy, Matthew.

In: Radiation Oncology, Vol. 14, No. 1, 18, 28.01.2019.

Research output: Contribution to journalArticle

Foster, Corey C. ; Sher, David J ; Rusthoven, Chad G. ; Verma, Vivek ; Spiotto, Michael T. ; Weichselbaum, Ralph R. ; Koshy, Matthew. / Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer : A National Cancer Database analysis. In: Radiation Oncology. 2019 ; Vol. 14, No. 1.
@article{803c0b458ea54db5b535fb6e37df4448,
title = "Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: A National Cancer Database analysis",
abstract = "Background: Preclinical studies suggest enhanced anti-tumor activity with combined radioimmunotherapy. We hypothesized that radiation (RT) + immunotherapy would associate with improved overall survival (OS) compared to immunotherapy or chemotherapy alone for patients with newly diagnosed metastatic non-small-cell lung cancer (NSCLC). Methods: The National Cancer Database was queried for patients with stage IV NSCLC receiving chemotherapy or immunotherapy from 2013 to 2014. RT modality was classified as stereotactic radiotherapy (SRT) to intra- and/or extracranial sites or non-SRT external beam RT (EBRT). OS was analyzed using the Kaplan-Meier method and Cox proportional hazards models. Results: In total, 44,498 patients were included (13{\%} immunotherapy, 46.8{\%} EBRT, and 4.7{\%} SRT). On multivariate analysis, immunotherapy (hazard ratio [HR]:0.81, 95{\%} confidence interval [CI]:0.78-0.83) and SRT (HR:0.78, 95{\%}CI:0.70-0.78) independently associated with improved OS; however, the interaction term for SRT + immunotherapy was insignificant (p = 0.89). For immunotherapy patients, the median OS for no RT, EBRT, and SRT was 14.5, 10.9, and 18.2 months, respectively (p < 0.0001), and EBRT (HR:1.37, 95{\%}CI:1.29-1.46) and SRT (HR:0.78, 95{\%}CI:0.66-0.93) associated with OS on multivariate analysis. In the SRT subset, median OS for immunotherapy and chemotherapy was 18.2 and 14.3 months, respectively (p = 0.004), with immunotherapy (HR:0.82, 95{\%}CI:0.69-0.98) associating with OS on multivariate analysis. Furthermore, for patients receiving SRT, biologically effective dose (BED) > 60 Gy was independently associated with improved OS (HR:0.79, 95{\%}CI:0.70-0.90, p < 0.0001) on multivariate analysis with a significant interaction between BED and systemic treatment (p = 0.008). Conclusions: Treatment with SRT associated with improved OS for patients with metastatic NSCLC irrespective of systemic treatment. The high survival for patients receiving SRT + immunotherapy strongly argues for evaluation in randomized trials.",
keywords = "Immunotherapy, National Cancer Database, Non-small-cell lung cancer, Radioimmunotherapy, Stereotactic radiotherapy",
author = "Foster, {Corey C.} and Sher, {David J} and Rusthoven, {Chad G.} and Vivek Verma and Spiotto, {Michael T.} and Weichselbaum, {Ralph R.} and Matthew Koshy",
year = "2019",
month = "1",
day = "28",
doi = "10.1186/s13014-019-1222-3",
language = "English (US)",
volume = "14",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer

T2 - A National Cancer Database analysis

AU - Foster, Corey C.

AU - Sher, David J

AU - Rusthoven, Chad G.

AU - Verma, Vivek

AU - Spiotto, Michael T.

AU - Weichselbaum, Ralph R.

AU - Koshy, Matthew

PY - 2019/1/28

Y1 - 2019/1/28

N2 - Background: Preclinical studies suggest enhanced anti-tumor activity with combined radioimmunotherapy. We hypothesized that radiation (RT) + immunotherapy would associate with improved overall survival (OS) compared to immunotherapy or chemotherapy alone for patients with newly diagnosed metastatic non-small-cell lung cancer (NSCLC). Methods: The National Cancer Database was queried for patients with stage IV NSCLC receiving chemotherapy or immunotherapy from 2013 to 2014. RT modality was classified as stereotactic radiotherapy (SRT) to intra- and/or extracranial sites or non-SRT external beam RT (EBRT). OS was analyzed using the Kaplan-Meier method and Cox proportional hazards models. Results: In total, 44,498 patients were included (13% immunotherapy, 46.8% EBRT, and 4.7% SRT). On multivariate analysis, immunotherapy (hazard ratio [HR]:0.81, 95% confidence interval [CI]:0.78-0.83) and SRT (HR:0.78, 95%CI:0.70-0.78) independently associated with improved OS; however, the interaction term for SRT + immunotherapy was insignificant (p = 0.89). For immunotherapy patients, the median OS for no RT, EBRT, and SRT was 14.5, 10.9, and 18.2 months, respectively (p < 0.0001), and EBRT (HR:1.37, 95%CI:1.29-1.46) and SRT (HR:0.78, 95%CI:0.66-0.93) associated with OS on multivariate analysis. In the SRT subset, median OS for immunotherapy and chemotherapy was 18.2 and 14.3 months, respectively (p = 0.004), with immunotherapy (HR:0.82, 95%CI:0.69-0.98) associating with OS on multivariate analysis. Furthermore, for patients receiving SRT, biologically effective dose (BED) > 60 Gy was independently associated with improved OS (HR:0.79, 95%CI:0.70-0.90, p < 0.0001) on multivariate analysis with a significant interaction between BED and systemic treatment (p = 0.008). Conclusions: Treatment with SRT associated with improved OS for patients with metastatic NSCLC irrespective of systemic treatment. The high survival for patients receiving SRT + immunotherapy strongly argues for evaluation in randomized trials.

AB - Background: Preclinical studies suggest enhanced anti-tumor activity with combined radioimmunotherapy. We hypothesized that radiation (RT) + immunotherapy would associate with improved overall survival (OS) compared to immunotherapy or chemotherapy alone for patients with newly diagnosed metastatic non-small-cell lung cancer (NSCLC). Methods: The National Cancer Database was queried for patients with stage IV NSCLC receiving chemotherapy or immunotherapy from 2013 to 2014. RT modality was classified as stereotactic radiotherapy (SRT) to intra- and/or extracranial sites or non-SRT external beam RT (EBRT). OS was analyzed using the Kaplan-Meier method and Cox proportional hazards models. Results: In total, 44,498 patients were included (13% immunotherapy, 46.8% EBRT, and 4.7% SRT). On multivariate analysis, immunotherapy (hazard ratio [HR]:0.81, 95% confidence interval [CI]:0.78-0.83) and SRT (HR:0.78, 95%CI:0.70-0.78) independently associated with improved OS; however, the interaction term for SRT + immunotherapy was insignificant (p = 0.89). For immunotherapy patients, the median OS for no RT, EBRT, and SRT was 14.5, 10.9, and 18.2 months, respectively (p < 0.0001), and EBRT (HR:1.37, 95%CI:1.29-1.46) and SRT (HR:0.78, 95%CI:0.66-0.93) associated with OS on multivariate analysis. In the SRT subset, median OS for immunotherapy and chemotherapy was 18.2 and 14.3 months, respectively (p = 0.004), with immunotherapy (HR:0.82, 95%CI:0.69-0.98) associating with OS on multivariate analysis. Furthermore, for patients receiving SRT, biologically effective dose (BED) > 60 Gy was independently associated with improved OS (HR:0.79, 95%CI:0.70-0.90, p < 0.0001) on multivariate analysis with a significant interaction between BED and systemic treatment (p = 0.008). Conclusions: Treatment with SRT associated with improved OS for patients with metastatic NSCLC irrespective of systemic treatment. The high survival for patients receiving SRT + immunotherapy strongly argues for evaluation in randomized trials.

KW - Immunotherapy

KW - National Cancer Database

KW - Non-small-cell lung cancer

KW - Radioimmunotherapy

KW - Stereotactic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85060651288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060651288&partnerID=8YFLogxK

U2 - 10.1186/s13014-019-1222-3

DO - 10.1186/s13014-019-1222-3

M3 - Article

VL - 14

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 18

ER -